Effect of MYC and PARP Inhibitors in Ovarian Cancer Using an In Vitro Model

Area of Science:

• Genetics and Genomics
• Oncology
• Molecular Biology

Background:

• The 8q24 chromosomal region, containing MYC and PVT1, is amplified in carcinomas and implicated in ovarian cancer (OC) pathogenesis.
• MYC and PVT1 are candidate oncogenes with known roles in various cancers.
• Previous studies suggest involvement of MYC and PVT1 in the development of ovarian cancer.

Purpose of the Study:

• To investigate MYC/PVT1 expression and copy number variation in OC using an in vitro model and in silico tools.
• To assess the effects of rucaparib (a PARP inhibitor) and 10058F4 (a MYC inhibitor) on MYC/PVT1 expression in OC.
• To explore potential interactions between MYC, PVT1, and other genes in OC.

Main Methods:

• In vitro ovarian cancer model with 8q24 copy number increase.
• In silico analysis using OncoDB, cBioportal, UALKAN, and ROC Plotter.
• Experimental techniques including tissue culture, RNA extraction, RT-qPCR, FISH, and wound healing assays.

Main Results:

• MYC and PVT1 expression levels were unaltered in OC, but MYC copy number alterations were marked.
• PVT1 expression demonstrated prognostic value in serous and endometrioid OC subtypes.
• Rucaparib, with or without 10058F4, significantly downregulated MYC, linear PVT1, and circular PVT1 expression in vitro.

Conclusions:

• A novel PARP inhibition mechanism down-regulating MYC, linear PVT1, and circular PVT1 transcripts was identified.
• MYC and PVT1 interactions with other genes offer new insights into OC pathogenesis.
• Further clinical studies are warranted to elucidate the prognostic role of PVT1 in OC.